uniQure (QURE) Competitors $16.98 +1.51 (+9.76%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends QURE vs. MLTX, JANX, EWTX, XENE, MRUS, TWST, ACAD, MOR, VCEL, and ZLABShould you be buying uniQure stock or one of its competitors? The main competitors of uniQure include MoonLake Immunotherapeutics (MLTX), Janux Therapeutics (JANX), Edgewise Therapeutics (EWTX), Xenon Pharmaceuticals (XENE), Merus (MRUS), Twist Bioscience (TWST), ACADIA Pharmaceuticals (ACAD), MorphoSys (MOR), Vericel (VCEL), and Zai Lab (ZLAB). These companies are all part of the "pharmaceutical products" industry. uniQure vs. MoonLake Immunotherapeutics Janux Therapeutics Edgewise Therapeutics Xenon Pharmaceuticals Merus Twist Bioscience ACADIA Pharmaceuticals MorphoSys Vericel Zai Lab MoonLake Immunotherapeutics (NASDAQ:MLTX) and uniQure (NASDAQ:QURE) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, community ranking, profitability, earnings, analyst recommendations, valuation and risk. Does the MarketBeat Community favor MLTX or QURE? uniQure received 591 more outperform votes than MoonLake Immunotherapeutics when rated by MarketBeat users. However, 80.52% of users gave MoonLake Immunotherapeutics an outperform vote while only 70.67% of users gave uniQure an outperform vote. CompanyUnderperformOutperformMoonLake ImmunotherapeuticsOutperform Votes6280.52% Underperform Votes1519.48%uniQureOutperform Votes65370.67% Underperform Votes27129.33% Does the media refer more to MLTX or QURE? In the previous week, uniQure had 1 more articles in the media than MoonLake Immunotherapeutics. MarketBeat recorded 9 mentions for uniQure and 8 mentions for MoonLake Immunotherapeutics. MoonLake Immunotherapeutics' average media sentiment score of 0.66 beat uniQure's score of 0.13 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MoonLake Immunotherapeutics 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive uniQure 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher earnings and valuation, MLTX or QURE? MoonLake Immunotherapeutics has higher earnings, but lower revenue than uniQure. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMoonLake ImmunotherapeuticsN/AN/A-$36.01M-$1.29-40.44uniQure$28.59M28.95-$308.48M-$4.96-3.42 Do analysts rate MLTX or QURE? MoonLake Immunotherapeutics presently has a consensus target price of $81.43, indicating a potential upside of 56.08%. uniQure has a consensus target price of $33.88, indicating a potential upside of 99.50%. Given uniQure's stronger consensus rating and higher possible upside, analysts clearly believe uniQure is more favorable than MoonLake Immunotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MoonLake Immunotherapeutics 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.88uniQure 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.00 Do insiders and institutionals have more ownership in MLTX or QURE? 93.8% of MoonLake Immunotherapeutics shares are held by institutional investors. Comparatively, 78.8% of uniQure shares are held by institutional investors. 12.0% of MoonLake Immunotherapeutics shares are held by company insiders. Comparatively, 4.7% of uniQure shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has more risk & volatility, MLTX or QURE? MoonLake Immunotherapeutics has a beta of 1.31, meaning that its share price is 31% more volatile than the S&P 500. Comparatively, uniQure has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500. Is MLTX or QURE more profitable? MoonLake Immunotherapeutics has a net margin of 0.00% compared to uniQure's net margin of -837.80%. MoonLake Immunotherapeutics' return on equity of -15.54% beat uniQure's return on equity.Company Net Margins Return on Equity Return on Assets MoonLake ImmunotherapeuticsN/A -15.54% -15.09% uniQure -837.80%-188.82%-32.17% SummaryMoonLake Immunotherapeutics beats uniQure on 10 of the 18 factors compared between the two stocks. Ad Weiss RatingsBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $125,000 by the end of his first month in office.This could be his favorite coin. Get uniQure News Delivered to You Automatically Sign up to receive the latest news and ratings for QURE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart QURE vs. The Competition Export to ExcelMetricuniQurePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$827.66M$6.57B$5.10B$9.08BDividend YieldN/A2.97%4.88%4.21%P/E Ratio-3.4210.5090.8317.14Price / Sales28.95195.361,112.01116.85Price / CashN/A57.1642.0237.88Price / Book3.915.104.774.78Net Income-$308.48M$151.51M$119.70M$225.60M7 Day Performance10.26%-2.11%-1.86%-1.23%1 Month Performance190.75%-3.11%11.45%3.07%1 Year Performance171.25%11.53%30.43%16.48% uniQure Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)QUREuniQure3.496 of 5 stars$16.98+9.8%$33.88+99.5%+172.3%$827.66M$28.59M-3.42500Analyst ForecastMLTXMoonLake Immunotherapeutics1.6318 of 5 stars$52.57+2.4%$79.88+51.9%-9.3%$3.36BN/A-39.802JANXJanux Therapeutics3.6249 of 5 stars$62.03+1.5%$89.90+44.9%+496.3%$3.26B$13.05M-52.2330EWTXEdgewise Therapeutics2.7347 of 5 stars$33.86+22.6%$42.33+25.0%+261.7%$3.21BN/A-22.8560Analyst ForecastAnalyst RevisionHigh Trading VolumeXENEXenon Pharmaceuticals2.8037 of 5 stars$40.94+2.2%$56.90+39.0%-5.8%$3.12B$9.43M-14.20251Insider TradeMRUSMerus2.8154 of 5 stars$42.93+0.2%$85.64+99.5%+61.7%$2.94B$35.93M-10.8437TWSTTwist Bioscience2.5589 of 5 stars$48.83+2.8%$51.90+6.3%+36.7%$2.90B$312.97M-13.19990ACADACADIA Pharmaceuticals3.839 of 5 stars$17.27+0.1%$25.60+48.2%-41.9%$2.87B$726.44M22.13510MORMorphoSys0.128 of 5 stars$18.96+2.4%$14.33-24.4%N/A$2.86B$238.28M-5.45730News CoverageVCELVericel1.4466 of 5 stars$57.35-0.2%$59.71+4.1%+66.0%$2.83B$226.84M957.83300Analyst ForecastZLABZai Lab1.7111 of 5 stars$26.03-1.1%$55.00+111.3%-7.4%$2.83B$355.75M-9.512,175 Related Companies and Tools Related Companies MLTX Alternatives JANX Alternatives EWTX Alternatives XENE Alternatives MRUS Alternatives TWST Alternatives ACAD Alternatives MOR Alternatives VCEL Alternatives ZLAB Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:QURE) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding uniQure Please log in to your account or sign up in order to add this asset to your watchlist. Share uniQure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free QURE Stock Alerts